NEWS

FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

May 28, 2019

Clinical Data Show 66.7% Pain Relief Response Within Two Hours

Read More

Model of personalized postprandial glycemic response to food developed for an Israeli cohort predicts responses in Midwestern American individuals.

May 16, 2019

Research paper published in the American Journal of Clinical Nutrition

Read More

Israel’s Zebra Medical gets FDA ok for AI chest X-ray product

May 13, 2019

Zebra Medical Vision said on Monday it received approval from the U.S. Food and Drug Administration for its artificial intelligence-based chest X-ray triage product.

Read More

Computational Pathology Pioneer Ibex Raises $11M

March 26, 2019

aMoon Fund leads round into developer of first ever clinically deployed AI Based Cancer Diagnosis system

Read More

Israeli migraine device co Theranica raises $35m

March 18, 2019

Nerivio Migra, the Netanya-based company’s novel remote neuromodulation device for acute treatment of migraine, is under review by the FDA.

Read More

Israeli health fund aMoon II raises $660 million

March 6, 2019

Israel-based healthcare fund aMoon II said on Wednesday it has received commitments of $660 million from investors. This is up from $600 million reported in January in an investor document obtained by Reuters.

Read More

A healthcare investment fund has become one of Israel’s largest with a $660 million close

March 6, 2019

One of Israel’s single largest venture capital funds is a new later stage vehicle focused on healthcare.

Read More

Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma

March 4, 2019

Results support the clinical development of AL101 as a targeted monotherapy for people with tumors bearing Notch activated mutations

Read More

Regenera Pharma Enrolls First Patient in US Phase 3 Study of RPh201 in NAION

August 2, 2018

Advances Phase 2 Study in Alzheimer’s Disease in Canada, RPh201 development in US supported by Fast Track Designation by US Food and Drug Administration

Read More

Israeli firm creates particles to kill germs on contact, fight bacterial disease

August 2, 2018

With product initially aimed for dental industry, Petah-Tikva based Nobio raises $3.6 million from aMoon Fund and Dr. Ole Jensen, a US surgeon and dentist

Read More

Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments

December 6, 2017

REHOVOT, Israel–(BUSINESS WIRE)–Ayala Pharmaceuticals, a biopharmaceutical company dedicated to developing targeted cancer therapies, announced today that they have entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for two gamma secretase inhibitors in development for the treatment of cancers with altered Notch genes.

Read More

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

August 17, 2017

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli healthcare and life science ventures, founded by Marius Nacht and Dr. Yair Schindel.

Read More

CartiHeal raises $18.3m to support PMA trial of Agili-C implant

May 8, 2017

CartiHeal said today it raised $18.3 million in a new round of financing to support an FDA IDE-approved clinical trial of its Agili-C implant for use in repairing cartilage and osteochondral defects.

Read More

Israeli Universal Flu Vaccine Maker Receives $2.8 Million Investment

January 4, 2017

Israeli billionaire Marius Nacht is banking on Israeli bio-tech with a $2.8 million investment into BiondVax Pharmaceuticals, a clinical phase company developing a universal flu vaccine.

Read More